Page 3 - EASL Recommendations on Treatment of Hepatitis C 2015 - Summary
P. 3
17. Tables
Table 1. Evidence grading used (adapted from the GRADE system).
Table 2. Indications for treatment of chronic hepatitis C in 2015: Who should be
treated and when?
Table 3. Approved HCV drugs in the European Union in 2015
Table 4A. Drug-drug interactions between HCV DAAs and HIV antiretrovirals
Table 4B. Drug-drug interactions between HCV DAAs and illicit recreational drugs
Table 4C. Drug-drug interactions between HCV DAAs and lipid lowering drugs
Table 4D. Drug-drug interactions between HCV DAAs and central nervous system
drugs
Table 4E. Drug-drug interactions between HCV DAAs and cardiovascular drugs
Table 4F. Drug-drug interactions between HCV DAAs and immunosuppressants
Table 5. Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected
patients with chronic hepatitis C without cirrhosis, including treatment-naïve
patients and patients who failed on a treatment based on PegIFN-α and ribavirin
(RBV)
Table 6. Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected
patients with chronic hepatitis C with compensated (Child-Pugh A) cirrhosis,
including treatment-naïve patients and patients who failed on a treatment based on
PegIFN-α and ribavirin (RBV)
Table 7. Treatment recommendations for retreatment of HCV-monoinfected or HCV/
HIV coinfected patients with chronic hepatitis C who failed to achieve an SVR on
prior antiviral therapy containing one or several DAA(s)
EASL Office Coordinator: Jean-Michel Pawlotsky
7 rue Daubin, 1203 Geneva, Switzerland
Tel: (+41) 22 807 03 67 Panel members: Alessio Aghemo (EASL governing board)
Fax: (+41) 22510 24 00 David Back
e-mail: easloffice@easloffice.eu Geoffrey Dusheiko
Xavier Forns
2 Massimo Puoti
Christoph Sarrazin
Table 1. Evidence grading used (adapted from the GRADE system).
Table 2. Indications for treatment of chronic hepatitis C in 2015: Who should be
treated and when?
Table 3. Approved HCV drugs in the European Union in 2015
Table 4A. Drug-drug interactions between HCV DAAs and HIV antiretrovirals
Table 4B. Drug-drug interactions between HCV DAAs and illicit recreational drugs
Table 4C. Drug-drug interactions between HCV DAAs and lipid lowering drugs
Table 4D. Drug-drug interactions between HCV DAAs and central nervous system
drugs
Table 4E. Drug-drug interactions between HCV DAAs and cardiovascular drugs
Table 4F. Drug-drug interactions between HCV DAAs and immunosuppressants
Table 5. Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected
patients with chronic hepatitis C without cirrhosis, including treatment-naïve
patients and patients who failed on a treatment based on PegIFN-α and ribavirin
(RBV)
Table 6. Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected
patients with chronic hepatitis C with compensated (Child-Pugh A) cirrhosis,
including treatment-naïve patients and patients who failed on a treatment based on
PegIFN-α and ribavirin (RBV)
Table 7. Treatment recommendations for retreatment of HCV-monoinfected or HCV/
HIV coinfected patients with chronic hepatitis C who failed to achieve an SVR on
prior antiviral therapy containing one or several DAA(s)
EASL Office Coordinator: Jean-Michel Pawlotsky
7 rue Daubin, 1203 Geneva, Switzerland
Tel: (+41) 22 807 03 67 Panel members: Alessio Aghemo (EASL governing board)
Fax: (+41) 22510 24 00 David Back
e-mail: easloffice@easloffice.eu Geoffrey Dusheiko
Xavier Forns
2 Massimo Puoti
Christoph Sarrazin
